An observational study in Charcot Joint of Foot and Osteoarthropathy, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Complications with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Complications · France.
Among the 11 studies in Diabetes Complications with a site in France, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 8th registered.
267 studies on the registry are indexed under Diabetes Complications; 54 are open to participants now.
Browse Diabetes Complications studies →3 of the 11 studies in Diabetes Complications with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
University Hospital, Toulouse · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 45 Diabetes Complications studies recruiting now, 27 (60%) set no upper age limit and 12 (27%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 200 across 84 observational studies indexed under Diabetes Complications.
Median enrollment 125 across the 7 interventional studies, 116 across the 4 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 8 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 3 studies filed under Diabetes Complications — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Complications with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07391995Centre Hospitalier Universitaire de NīmesNew Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis | 2027-06 |
| NCT05491577Centre Hospitalier Universitaire de NīmesFactors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot | 2027-07-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Complications with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Charcot foot, characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot, is a complication of diabetes that is still poorly understood by patients and caregivers. The clinical signs are non-specific and it is therefore largely underestimated due to a delay in diagnosis/lack of diagnosis.This study will be on a prospective multicenter cohort of patients with chronic Charcot's foot in France to evaluate the evolution of quality of life at 2 years, as well as predictive factors in order to better identify subjects with the worst outcome among this population.
Our hypothesis is that, in patients with chronic Charcot foot, the deterioration in quality of life over time is primarily related to loss of foot and ankle functionality, foot and ankle deformity and the presence of foot wounds/comorbidities/severe diabetic complications.
Diabetes mellitus is a chronic disease, representing a major public health problem. An estimated 537 million people have diabetes. Charcot foot, also known as neurogenic osteoarthropathy (NAO), is one of the complications of diabetes secondary to diabetic neuropathy. It is characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot. Charcot foot is a complication of diabetes that is still poorly understood by patients and caregivers, with non-specific clinical signs. It is therefore largely underestimated, since it is estimated that there is a delay in diagnosis or a lack of diagnosis in approximately 25% of cases.
The objective of our study is to conduct a prospective multicenter cohort of patients with chronic Charcot's foot in France in order to evaluate the evolution of the quality of life at 2 years, as well as its predictive factors. In this way, we will be better able to identify the subjects with the worst outcome among the chronic Charcot foot population.
Our hypothesis is that the deterioration in quality of life over time in patients with chronic Charcot foot is primarily related to loss of foot and ankle functionality, foot and ankle deformity, the presence of foot wounds and/or comorbidities or severe diabetic complications.
The source population corresponds to all diabetic patients (Type 1, 2 or secondary diabetes) hospitalized or consulting for chronic diabetic osteoarthropathy of the nerves, without wound managed in the participating centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
Results of the SF36 questionnaire at inclusion
The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.
Time frame: Day 0
Results of the FAAM-F questionnaire at inclusion
The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.
Time frame: Day 0
Results of the SF36 questionnaire at Month 12
The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.
Time frame: Month 12
Results of the FAAM-F questionnaire at Month 12
The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.
Time frame: Month 12
Results of the SF36 questionnaire at Month 24
The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.
Time frame: Month 24
Results of the FAAM-F questionnaire at Month 24
The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.
Time frame: Month 24
A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)
In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.
Time frame: Day 0
A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)
In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.
Time frame: Month 12
A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)
In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.
Time frame: Month 24
A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.
Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.
Time frame: Day 0
A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.
Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.
Time frame: Month 12
A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.
Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.
Time frame: Month 24
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope
The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.
Time frame: Day 0
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope
The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.
Time frame: Month 12
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope
The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.
Time frame: Month 24
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle
The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.
Time frame: Day 0
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle
The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.
Time frame: Month 12
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle
The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.
Time frame: Month 24
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment
The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..
Time frame: Day 0
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment
The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..
Time frame: Month 12
A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment
The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Retinopathy
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Retinopathy
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure
YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure
YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure
YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes
YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes
YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes
YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension
Pressure over 140/90mmHg : YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension
Pressure over 140/90mmHg : YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension
Pressure over 140/90mmHg : YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking
Does the patient smoke : YES/NO
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking
Does the patient smoke : YES/NO
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking
Does the patient smoke : YES/NO
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status
Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status
Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status
Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score
Time frame: Month 24
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index
The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.
Time frame: Day 0
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index
The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.
Time frame: Month 12
B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index
The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.
Time frame: Month 24
C. Medical and/or surgical treatment for Charcot foot.
All medical and/or surgical treatment for Charcot foot will be recorded.
Time frame: Day 0
C. Medical and/or surgical treatment for Charcot foot.
All medical and/or surgical treatment for Charcot foot will be recorded.
Time frame: Month 12
C. Medical and/or surgical treatment for Charcot foot.
All medical and/or surgical treatment for Charcot foot will be recorded.
Time frame: Month 24
D. Incidence of hospitalization
The number of hospitalizations (if any) will be noted.
Time frame: Month 12
D. Incidence of hospitalization
The number of hospitalizations (if any) will be noted.
Time frame: Month 24
E. Presence of a wound/wounds
YES/NO and number thereof.
Time frame: Month 12
E. Presence of a wound/wounds
YES/NO and number thereof.
Time frame: Month 24
E. Presence of an infection
YES/NO
Time frame: Month 12
E. Presence of an infection
YES/NO
Time frame: Month 24
F. Presence of an amputation at inclusion
YES/NO (or, if planned, time to amputation in days).
Time frame: Day 0
G. Estimated incidence of amputations
YES/NO (or, if planned, time to amputation in days).
Time frame: Month 12
G. Presence of an amputation
YES/NO (or, if planned, time to amputation in days).
Time frame: Month 24
H. Precarity of patients with chronic Charcot foot.
The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.
Time frame: Day 0
H. Precarity of patients with chronic Charcot foot.
The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.
Time frame: Month 12
H. Precarity of patients with chronic Charcot foot.
The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.
Time frame: Month 24
I. Depression according to the PHQ-2 self-questionnaire
The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.
Time frame: Day 0
I. Depression according to the PHQ-2 self-questionnaire
The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.
Time frame: Month 24
I. Depression according to the PHQ-2 self-questionnaire
The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.
Time frame: Month 12
I. Depression according to the PHQ-9 self-questionnaire
The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.
Time frame: Day 0
I. Depression according to the PHQ-9 self-questionnaire
The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.
Time frame: Month 12
I. Depression according to the PHQ-9 self-questionnaire
The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.
Time frame: Month 24
J. Mortality rate
Vital status (dead/alive)
Time frame: Month 12
J. Mortality rate
Vital status (dead/alive)
Time frame: Month 24
K. Sanders Classification of the Charcot Foot
The Sanders classification will be used to assess the degree of damage to the patient's foot as follows : Sanders I = Metatarsophalangeal involvement (forefoot) Sanders II= Tarsometatarsal joint involvement Sanders III= Tarsal joints involvement Sanders IV= Ankle involvement Sanders V= Posterior calcaneus involvement (tuberosity of the calcaneus, avulsion of the Achilles tendon) and all information will be recorded for the evaluation of the patient's quality of life.
Time frame: Day 0
K. Sanders Classification of the Charcot Foot
The Sanders classification will be used to assess the degree of damage to the patient's foot as follows : Sanders I = Metatarsophalangeal involvement (forefoot) Sanders II= Tarsometatarsal joint involvement Sanders III= Tarsal joints involvement Sanders IV= Ankle involvement Sanders V= Posterior calcaneus involvement (tuberosity of the calcaneus, avulsion of the Achilles tendon) and all information will be recorded for the evaluation of the patient's quality of life.
Time frame: Month 12
Sex of patients
MALE/FEMALE
Time frame: Day 0
Age of patients
In years
Time frame: Day 0
Patient's personal situation
Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy
Time frame: Day 0
Patient's personal situation
Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy
Time frame: Month 12
Patient's personal situation
Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy
Time frame: Month 24
Patient's level of education
The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).
Time frame: Day 0
Patient's level of education
The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).
Time frame: Month 12
Patient's level of education
The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).
Time frame: Month 24
Patient's professional activity
The patient's professional activity (if any) will be recorded
Time frame: Day 0
Patient's professional activity
The patient's professional activity (if any) will be recorded
Time frame: Month 12
Patient's professional activity
The patient's professional activity (if any) will be recorded
Time frame: Month 24
Nature of diabetes
The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).
Time frame: Day 0
Nature of diabetes
The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).
Time frame: Month 12
Nature of diabetes
The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).
Time frame: Month 24
Age of diabetes
The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).
Time frame: Day 0
Age of diabetes
The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).
Time frame: Month 12
Age of diabetes
The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).
Time frame: Month 24
Presence of other complications: Retinopathy
YES/NO
Time frame: Day 0
Presence of other complications: Retinopathy
YES/NO
Time frame: Month 12
Presence of other complications: Retinopathy
YES/NO
Time frame: Month 24
Presence of other complications: decreased visual acuity
YES/NO
Time frame: Day 0
Presence of other complications: decreased visual acuity
YES/NO
Time frame: Month 12
Presence of other complications: decreased visual acuity
YES/NO
Time frame: Month 24
Presence of other complications: Nephropathy
YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)
Time frame: Day 0
Presence of other complications: Nephropathy
YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)
Time frame: Month 12
Presence of other complications: Nephropathy
YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)
Time frame: Month 24
Presence of other complications: Abnormal glomerular filtration rate (GFR)
GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²
Time frame: Day 0
Presence of other complications: Abnormal glomerular filtration rate (GFR)
GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²
Time frame: Month 12
Presence of other complications: Abnormal glomerular filtration rate (GFR)
GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²
Time frame: Month 24
Presence of other complications: dialysis
YES/NO
Time frame: Day 0
Presence of other complications: dialysis
YES/NO
Time frame: Month 12
Presence of other complications: dialysis
YES/NO
Time frame: Month 24
Presence of other complications: peripheral neuropathy
YES/NO and the nature thereof: monofilament (normal, pathological, not done)
Time frame: Day 0
Presence of other complications: peripheral neuropathy
YES/NO and the nature thereof: monofilament (normal, pathological, not done)
Time frame: Month 12
Presence of other complications: peripheral neuropathy
YES/NO and the nature thereof: monofilament (normal, pathological, not done)
Time frame: Month 24
Presence of other complications: vegetative neuropathy
YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)
Time frame: Day 0
Presence of other complications: vegetative neuropathy
YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)
Time frame: Month 12
Presence of other complications: vegetative neuropathy
YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)
Time frame: Month 24
Presence of other complications: coronaropathy
YES/NO
Time frame: Day 0
Presence of other complications: coronaropathy
YES/NO
Time frame: Month 12
Presence of other complications: coronaropathy
YES/NO
Time frame: Month 24
Presence of other complications: heart failure
YES/NO
Time frame: Day 0
Presence of other complications: heart failure
YES/NO
Time frame: Month 12
Presence of other complications: heart failure
YES/NO
Time frame: Month 24
Presence of other complications: arteriopathy of the lower limbs
YES/NO and the nature thereof (revascularised or not/left or right side)
Time frame: Day 0
Presence of other complications: arteriopathy of the lower limbs
YES/NO and the nature thereof (revascularised or not/left or right side)
Time frame: Month 12
Presence of other complications: arteriopathy of the lower limbs
YES/NO and the nature thereof (revascularised or not/left or right side)
Time frame: Month 24
Presence of other complications: involvement of the supra-aortic trunk
YES/NO
Time frame: Day 0
Presence of other complications: involvement of the supra-aortic trunk
YES/NO
Time frame: Month 12
Presence of other complications: involvement of the supra-aortic trunk
YES/NO
Time frame: Month 24
Presence of other complications: stroke
YES/NO
Time frame: Day 0
Presence of other complications: stroke
YES/NO
Time frame: Month 12
Presence of other complications: stroke
YES/NO
Time frame: Month 24
Presence of other complications: sequellar hemiplegia
YES/NO
Time frame: Day 0
Presence of other complications: sequellar hemiplegia
YES/NO
Time frame: Month 12
Presence of other complications: sequellar hemiplegia
YES/NO
Time frame: Month 24
Treatments: oral antidiabetics
The nature of all oral antidiabetics will be recorded.
Time frame: Day 0
Treatments: oral antidiabetics
The nature of all oral antidiabetics will be recorded.
Time frame: Month 12
Treatments: oral antidiabetics
The nature of all oral antidiabetics will be recorded.
Time frame: Month 24
Treatments: injectable antidiabetics
The nature of all injectable antidiabetics will be recorded.
Time frame: Day 0
Treatments: injectable antidiabetics
The nature of all injectable antidiabetics will be recorded.
Time frame: Month 12
Treatments: injectable antidiabetics
The nature of all injectable antidiabetics will be recorded.
Time frame: Month 24
Other treatments
The nature of all other treatments will be recorded.
Time frame: Day 0
Other treatments
The nature of all other treatments will be recorded.
Time frame: Month 12
Other treatments
The nature of all other treatments will be recorded.
Time frame: Month 24
History of trophic disorders
YES/NO and, if so, left/right, both feet.
Time frame: Day 0
History of trophic disorders
YES/NO and, if so, left/right, both feet.
Time frame: Month 12
History of trophic disorders
YES/NO and, if so, left/right, both feet.
Time frame: Month 24
Regular pedicure treatments
The number and frequency of pedicure sessions per year will be recorded (if any).
Time frame: Day 0
Regular pedicure treatments
The number and frequency of pedicure sessions per year will be recorded (if any).
Time frame: Month 12
Regular pedicure treatments
YES/NO and, if so, number and frequency of pedicure sessions per year will be recorded (if any).
Time frame: Month 24
Weight
Kilos
Time frame: Day 0
Weight
Kilos
Time frame: Month 12
Weight
Kilos
Time frame: Month 24
Height
Centimeters
Time frame: Day 0
Height
Centimeters
Time frame: Month 12
Height
Centimeters
Time frame: Month 24
Charcot foot
Left/right/both
Time frame: Day 0
Charcot foot
Left/right/both
Time frame: Month 12
Charcot foot
Left/right/both
Time frame: Month 24
Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy
In years
Time frame: Day 0
Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy
In years
Time frame: Month 12
Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy
In years
Time frame: Month 24
Neurogenic osteoarthropathy Sanders classification
Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum
Time frame: Day 0
Neurogenic osteoarthropathy Sanders classification
Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum
Time frame: Month 12
Neurogenic osteoarthropathy Sanders classification
Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum
Time frame: Month 24
Current mode of shoeing/unfastening at home
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Day 0
Current mode of shoeing/unfastening outdoors
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Day 0
Current mode of shoeing/unfastening at home
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Month 12
Current mode of shoeing/unfastening outdoors
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Month 12
Current mode of shoeing/unfastening at home
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Month 24
Current mode of shoeing/unfastening outdoors
Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...
Time frame: Month 24
Adherence to shoeing method
At home/outdoors
Time frame: Day 0
Adherence to shoeing method
At home/outdoors
Time frame: Month 12
Adherence to shoeing method
At home/outdoors
Time frame: Month 24
Presence of another trophic foot disorder during the previous year
YES/NO and date of onset of the ulcer (month and year)
Time frame: Day 0
Presence of another trophic foot disorder during the previous year
YES/NO and date of onset of the ulcer (month and year)
Time frame: Month 12
Presence of another trophic foot disorder during the previous year
YES/NO and date of onset of the ulcer (month and year)
Time frame: Month 24
Presence of a clinical infection
YES/NO and, if so, the Infectious Diseases Society of America classification
Time frame: Day 0
Presence of a clinical infection
YES/NO and, if so, the Infectious Diseases Society of America classification
Time frame: Month 12
Presence of a clinical infection
YES/NO and, if so, the Infectious Diseases Society of America classification
Time frame: Month 24
Foot or leg surgery in the previous year
YES/NO and, if so, left/right
Time frame: Day 0
Foot or leg surgery in the previous year
YES/NO and, if so, left/right
Time frame: Month 12
Foot or leg surgery in the previous year
YES/NO and, if so, left/right
Time frame: Month 24
Partial foot amputation
YES/NO and, if so, left/right
Time frame: Day 0
Partial foot amputation
YES/NO and, if so, left/right
Time frame: Month 12
Partial foot amputation
YES/NO and, if so, left/right
Time frame: Month 24
Trans-tibial amputation
YES/NO and, if so, left/right
Time frame: Day 0
Trans-tibial amputation
YES/NO and, if so, left/right
Time frame: Month 12
Trans-tibial amputation
YES/NO and, if so, left/right
Time frame: Month 24
Trans-femoral amputation
YES/NO and, if so, left/right
Time frame: Day 0
Trans-femoral amputation
YES/NO and, if so, left/right
Time frame: Month 12
Trans-femoral amputation
YES/NO and, if so, left/right
Time frame: Month 24
Other type of surgery
All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.
Time frame: Day 0
Other type of surgery
All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.
Time frame: Month 12
Other type of surgery
All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.
Time frame: Month 24
Hospitalization in the previous year
YES/NO and, if so, the reason why
Time frame: Day 0
Hospitalization in the previous year
YES/NO and, if so, the reason why
Time frame: Month 12
Hospitalization in the previous year
YES/NO and, if so, the reason why
Time frame: Month 24
Onset and management of a foot wound (medical or surgical)
YES/NO and dates
Time frame: Day 0
Onset and management of a foot wound (medical or surgical)
YES/NO and dates
Time frame: Month 12
Onset and management of a foot wound (medical or surgical)
YES/NO and dates
Time frame: Month 24
Management of a Charcot foot
YES/NO
Time frame: Day 0
Management of a Charcot foot
YES/NO
Time frame: Month 12
Management of a Charcot foot
YES/NO
Time frame: Month 24
Onset of a controlateral Charcot foot
YES/NO
Time frame: Day 0
Onset of a controlateral Charcot foot
YES/NO
Time frame: Month 12
Onset of a controlateral Charcot foot
YES/NO
Time frame: Month 24
Diabetic imbalance
YES/NO
Time frame: Day 0
Diabetic imbalance
YES/NO
Time frame: Month 12
Diabetic imbalance
YES/NO
Time frame: Month 24
Other comorbidity or other reason for surgery
YES/NO
Time frame: Day 0
Other comorbidity or other reason for surgery
YES/NO
Time frame: Month 12
Other comorbidity or other reason for surgery
YES/NO
Time frame: Month 24
Monitoring of glycemic control by HbA1c
HbA1c will be measured as a percentage
Time frame: Day 0
Monitoring of glycemic control by HbA1c
HbA1c will be measured as a percentage
Time frame: Month 12
Monitoring of glycemic control by HbA1c
HbA1c will be measured as a percentage
Time frame: Month 24
Monitoring of glomerular Filtration Rate
ml/mn
Time frame: Day 0
Monitoring of glomerular Filtration Rate
ml/mn
Time frame: Month 12
Monitoring of glomerular Filtration Rate
ml/mn
Time frame: Month 24
X-ray of Charcot foot under loading (profile view)
Measurement of the Djian Annonier angle and the Meary-Tomeno line
Time frame: Day 0
X-ray of Charcot foot under loading (profile view)
Measurement of the Djian Annonier angle and the Meary-Tomeno line
Time frame: Month 12
X-ray of Charcot foot under loading (profile view)
Measurement of the Djian Annonier angle and the Meary-Tomeno line
Time frame: Month 24
Front view X-ray of the ankle(s) under loading
With Meary cerclage (metal cerclage of the hindfoot)
Time frame: Day 0
Front view X-ray of the ankle(s) under loading
With Meary cerclage (metal cerclage of the hindfoot)
Time frame: Month 12
Front view X-ray of the ankle(s) under loading
With Meary cerclage (metal cerclage of the hindfoot)
Time frame: Month 24
Started Jan 2023 (actual). Primary completion is estimated for Jul 2027, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →